TG Therapeutics: The Hype Is Gone (NASDAQ:TGTX)

Business graph with arrows tending downwards


Shares of TG Therapeutics (NASDAQ:TGTX) plunged after the company missed the Q2 2023 revenue estimate and as it signed an ex-U.S. deal with Neuraxpharm for Briumvi.

The revenue miss would not be such a problem if the underlying

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *